Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma

HPB : the Official Journal of the International Hepato Pancreato Biliary Association
Guanghua LiuDengbin Wang

Abstract

To investigate the clinical value of the alpha-fetoprotein (AFP) response following transcatheter arterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma (HCC). Data on patients with Barcelona Clinic Liver Cancer B staging system were analyzed. An AFP response was defined as a decrease in AFP of more than 20% after a TACE session. The association between AFP response and treatment outcome regarding imaging response and overall survival (OS) was explored. Cox proportional hazards models were applied to identify independent risk factors for OS after TACE. Of the enrolled 376 patients with elevated serum AFP >20 ng/mL, 214 (57%) with AFP responses were identified. AFP responders had improved median survival than non-responders (20 vs. 12 months, P = 0.002). AFP response was significantly correlated with imaging response (P < 0.001). The Cox proportional hazards model revealed that AFP response was an independent factor for OS (hazard ratio, 0.59; 95% confidence interval, 0.45-0.78; P < 0.001). In stratified analyses, an AFP response achieved improved survival in patients with tumor diameters ≤5 cm, diameters >5 cm, tumor number ≤3 and without underlying cirrhosis. The AFP response indicates enhanced surviv...Continue Reading

References

May 1, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chung-Mau LoJohn Wong
Jan 24, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Josep M Llovet, Jordi Bruix
Oct 27, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordi BruixUNKNOWN Practice Guidelines Committee, American Association for the Study of Liver Diseases
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen L ChanWinnie Yeo
Apr 23, 2009·Journal of Gastroenterology and Hepatology·Deepak AmarapurkarUNKNOWN Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma
Oct 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ahsun RiazRiad Salem
Apr 17, 2010·Digestive Diseases and Sciences·Faisal M SanaiAyman A Abdo
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Feb 26, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Rita GolfieriLuigi Bolondi
Mar 5, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordi BruixUNKNOWN American Association for the Study of Liver Diseases
Mar 25, 2015·Journal of Gastroenterology and Hepatology·Guanghua LiuFeng Shen
Mar 23, 2017·Journal of Hepatology·Peter R GalleLuigi Bolondi

❮ Previous
Next ❯

Citations

Apr 11, 2020·Annals of Surgical Treatment and Research·Hyunyou KimMyunghee Yoon
May 28, 2021·World Journal of Gastrointestinal Oncology·Ming-Cheng GuanTian Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.